Breaking News, Trials & Filings

Trials & Filings in Brief: Dec. 11, 2013

AbbVie, Avanir, Baxter, Genzyme, KaloBios, Merck, Orexigen, QRxPharma, Seattle Genetics

Phase I
KaloBios succeeds in early-stage trial . . . read more

Phase II
Seattle Genetics updates Adcetris DLBCL data . . . read more

Phase III
AbbVie regimen wallops HCV . . . read more

Avanir pain drug misses endpoint in MS pain trial . . . read more

Merck advances Alzheimer’s drug . . . read more

Filings
Baxter submits OBI-1 BLA . . . read more

Genzyme Gaucher treatment gets priority review . . . read more

Orexigen resubmits Contrave NDA . . . read more

QRxPharma MOXDUO PDUFA date announced . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters